According to the new market research report “High Throughput Process Development Market by Product (Consumables (Minicolumn, Mini Bioreactor), Instruments), Services, Software, Molecule Type (mAB), Technology (Affinity Chromatography), End User (Biopharmaceutical) – Global Forecast to 2021″, published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities.
Growth in the high throughput process development market is mainly driven by increasing R&D spending, technological advancements in process development, growth in the biopharmaceutical industry, and the increasing pressure to lower manufacturing costs.
Download PDF Brochure – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=10249359
By molecule type, the market is classified into monoclonal antibodies and others (recombinant pro-insulin, polysaccharide vaccines, recombinant Green Fluorescent Protein (rGFP), fusion proteins, and interferon á-2a). The monoclonal antibodies segment accounted for the largest share of the global market in 2016. The large share of this segment is attributed to the increasing adoption of targeted immunotherapy and the increasing number of FDA-cleared therapeutic.
Based on end user, the market is categorized into biopharmaceutical companies, contract research organizations and academic research institutes. Biopharmaceutical companies accounted for the largest share of the global high throughput process development market in 2016.
The contract manufacturing organizations segment, on the other hand, is expected to be the fastest-growing end-user segment of the market during the forecast period. High R&D investments by pharmaceutical and biopharmaceutical companies to accelerate drug manufacturing and increasing pressure from regulatory authorities to lower the cost of production are the major factors driving the growth of the biopharmaceutical manufacturers end-user segment.
Request for Sample Pages – https://www.marketsandmarkets.com/requestsampleNew.asp?id=10249359
Based on technology, the market is categorized into chromatography, ultraviolet-visible spectroscopy, and others (ELISA, chip electrophoresis, SPR, and qPCR). The chromatography segment accounted for the largest share of the global high throughput process development market in 2016. The chromatography segment is further divided into ion exchange chromatography (IEC), affinity chromatography (AC), multimodal chromatography (MC), and others (hydrophobic charge induction chromatography (HCIC) and size exclusion chromatography).
The affinity chromatography segment accounted for the largest share of the chromatography high throughput process development in 2016. Owing to the advantages of affinity chromatography over other chromatography such as high selectivity, high flow rate and its capacity for extensive removal of process-related impurities such as host cell proteins, DNA, and cell culture media component are driving the growth of the market.
Geographically, North America (comprising the US and Canada) accounted for the largest share of the global high throughput process development market in 2016.
Major players operating in the market include Danaher (US), GE Healthcare (US), Agilent Technologies (US), Merck Millipore (Germany), and Thermo Fisher Scientific (US).
Speak to our expert about High Throughput Process Development Market – https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=10249359